Are we ready to prescribe a polypill to our patients?

The all-in-one pill combination (Polypill) of several active components used in primary prevention of cardiovascular disease was a decade ago purposed to reduce the cardiovascular burden by more than 80%. This Polypill could be approved before 2013 in United States. Although controversed, it could a...

Full description

Bibliographic Details
Published in:Revue medicale suisse, Vol. 8, No. 360 (2012), p. 2046, 2048-51
Main Author: Castioni, J
Other Involved Persons: Mooser, V ; Waeber, G
Format: Article
Language:French
ISSN:1660-9379
Item Description:Date Completed 09.01.2013
Date Revised 27.11.2012
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Subjects:
QR Code: Show QR Code
LEADER 02253naa a2200457 c 4500
001 NLM222867183
003 DE-601
005 20181228124902.0
008 180205s2012 000 0 fre d
028 5 2 |a pubmed19n0743.xml 
035 |a (DE-599)NLM23185925 
040 |b ger  |c GBVCP 
041 0 |a fre 
100 1 |a Castioni, J 
245 1 0 |a Are we ready to prescribe a polypill to our patients? 
246 3 |a Sommes-nous prêts à prescrire une polypill à nos patients? 
500 |a Date Completed 09.01.2013 
500 |a Date Revised 27.11.2012 
500 |a published: Print 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a The all-in-one pill combination (Polypill) of several active components used in primary prevention of cardiovascular disease was a decade ago purposed to reduce the cardiovascular burden by more than 80%. This Polypill could be approved before 2013 in United States. Although controversed, it could answer to the worried situation even observed in Switzerland: the adherence to secondary prevention treatments is clearly insufficient and the cardiovascular events remain in the first row of death's causes. This abstract summarize the results from interventional studies who tried to valid this concept as well as the main stakes to be assessed on the medical side before to consider such a similar approach in Switzerland 
611 2 7 |a English Abstract  |2 gnd 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Cardiovascular Diseases  |6 D002318  |a *prevention & control  |6 Q000517 
653 2 |a *Drug Combinations  |6 D004338 
653 2 |a Humans  |6 D006801 
653 2 |a Primary Prevention  |6 D011322 
653 2 |a Randomized Controlled Trials as Topic  |6 D016032 
655 7 |a Drug Combinations  |2 gnd 
689 0 0 |A f  |a English Abstract 
689 0 1 |A f  |a Journal Article 
689 0 |5 DE-601 
689 2 0 |a Drug Combinations 
689 2 |5 DE-601 
700 1 |a Mooser, V 
700 1 |a Waeber, G 
773 0 8 |i in  |t Revue medicale suisse  |g Vol. 8, No. 360 (2012), p. 2046, 2048-51  |q 8:360<2046, 2048-51  |w (DE-601)NLM154248010  |x 1660-9379 
912 |a GBV_NLM 
951 |a AR 
952 |d 8  |j 2012  |e 360  |c 10  |h 2046, 2048-51